Breviscapine combined with BMSCs treatment can reduce Abeta deposition in AD rats and promote the degradation of APP and BAEC1 by activating NF-kB to promote UCHL1 expression.
Breviscapine Combined with BMSCs Reduces Abeta Deposition in Rat with Alzheimer Disease by Regulating Circular RNA ciRS-7.